The Valley Desk

NCT04300556 · Interventional trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Overall registry status Recruiting

Phase 1 · Phase 2

Conditions Solid Tumor

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov